Nidec Announces Its Policy for Developing the Improvement Plan
KYOTO, Japan–(BUSINESS WIRE)–As explained in the press release dated October 28, 2025, “Notice Regarding Designation of Security on Special Alert... Read more.
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
Appointed Mark Nawacki, seasoned M&A expert, co-founder, president & former CEO of Searchlight Pharma, to Board of Directors Completed IND submission to... Read more.
HASI Prices Offering of $500 Million of Green Junior Subordinated Notes
ANNAPOLIS, Md.–(BUSINESS WIRE)–HA Sustainable Infrastructure Capital, Inc. (“HASI,” “our,” “we,” or the “Company”)... Read more.
NMG’s Matawinie Mine recognized as a “Major Project of National Interest” by the Government of Canada
Referral of NMG’s Phase-2 Matawinie Mine to the Government of Canada’s Major Projects Office to support and accelerate the development of an integrated... Read more.
Nidec Announces the Record of Provisions for Loss on Contract, Impairment Losses on Non-Financial Assets, and Liabilities Related to the Settlement of Claims From Suppliers
KYOTO, Japan–(BUSINESS WIRE)–Nidec Corporation (TSE: 6594; OTC US: NJDCY) (the “Company”) announces the Company recorded provisions for... Read more.
Update on Phase 3 Librexia ACS Trial
Independent, scheduled review finds Librexia ACS trial unlikely to meet primary efficacy endpoint, leading to decision to discontinue trial Librexia AF and Librexia... Read more.
Nidec Announces Disclaimer of Conclusion in the Interim Review Report Concerning the Semi-annual Report for the Six Months Ended September 30, 2025
KYOTO, Japan–(BUSINESS WIRE)–Nidec Corporation (the “Company”) has received the interim review report containing a disclaimer of conclusion... Read more.
Nidec Announces Financial Results for Fiscal First Quarter Ended June 30, 2025
KYOTO, Japan–(BUSINESS WIRE)–Nidec Corporation (TOKYO: 6594) (OTC US: NJDCY) today announced its consolidated results under the International Financial... Read more.
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk... Read more.
AIRO Reports Third Quarter 2025 Results; Progress on Drone Deliveries and Strong Liquidity Position
AIRO, Through Its Leading Drone Technology Business, Sky-Watch, Secures $4.5M Development Program to Advance Counter-Electronic Warfare Technologies MCLEAN, Va.–(BUSINESS... Read more.